| Schedule of Revenue, Significant Expenses, and Net (Loss) Income |
The following table presents the revenue, significant expenses, and net loss for the Company’s single reportable segment: | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | 2026 | | 2025 | | 2026 | | 2025 | | | | | | | | | | Significant and Other Segment Expenses | | | | | | | | | General and Administrative | $ | 1,383,504 | | | $ | 1,353,850 | | | 2,995,771 | | | 2,843,248 | | | Research and Development | | | | | | | | | KIO-101 | — | | | 3,780 | | | — | | | 6,795 | | | KIO-1041 | 267,155 | | | 426,347 | | | 554,164 | | | 277,022 | | | KIO-301 | 1,748,759 | | | 2,125,633 | | | 3,308,866 | | | 4,227,484 | | | Unallocated R&D Expenses2 | 61,202 | | | 34,729 | | | 337,811 | | | 611,076 | | | Total Research & Development | 2,077,116 | | | 2,590,489 | | | 4,200,841 | | | 5,122,377 | | | KIO-301 Collaboration Credit | (1,336,263) | | | (1,685,917) | | | (2,569,487) | | | (3,652,040) | | | | | | | | | | | | | | | | | | | Change in Fair Value of Contingent Consideration | 89,414 | | | 137,774 | | | 96,841 | | | 412,966 | | | Interest Income, Net | (146,232) | | | (225,237) | | | (285,570) | | | (397,703) | | | Other Segment Expenses3 | 10,672 | | | 93,556 | | | 57,798 | | | 5,642 | | | Income Tax Provision | 800 | | | (112,057) | | | 800 | | | 10,949 | | | Net Loss | $ | (2,079,011) | | | $ | (2,152,459) | | | $ | (4,496,994) | | | $ | (4,345,439) | |
1 Net of research tax credit offset. 2 Unallocated research and development expenses primarily include personnel costs, research consulting and scientific advisory expenses. 3 Other segment expenses primarily include interest expense, other income, net, and loss on disposal of fixed assets.
|